Results 111 to 120 of about 26,004 (264)

Mechanisms of spinal glial activation in chemotherapy‐induced peripheral neuropathy: Focus on microglia and astrocytes

Ibrain, EarlyView.
Chemotherapy‐induced peripheral neuropathy (CIPN) remains a major clinical challenge, with central sensitization considered an important pathological mechanism in its occurrence and persistence. This review focuses on spinal astrocytes and microglia, systematically summarizing the pathological mechanisms of spinal glial cells involved in CIPN caused by
Long Gu, Song Cao, Yonghuai Feng
wiley   +1 more source

2207

Journal of Clinical and Translational Science, 2017
OBJECTIVES/SPECIFIC AIMS: Patients with locally advanced pancreatic cancer typically have poor outcomes, with a median survival of ~16 months. Novel methods to improve local control are needed.
Jacob Ezra Shabason, Jerry Chen, Smith Apisarnthanarax, Nevena Damjanov, Bruce Giantonio, Arturo Loaiza-Bonilla, Peter O’Dwyer, Mark O’Hara, Kim Reiss, Ursina Teitelbaum, Paul Wissel, Jeffery Drebin, Charles Vollmer, Michael Kochman, Rosemarie Mick, Norge Vergara, Nirag Jhala, Abigail Berman, Jay Dorsey, Sydney M. Evans, Gary Kao, John N. Lukens, John P. Plastaras, James M. Metz, Edgar Ben-Josef   +24 more
doaj   +1 more source

Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer [PDF]

, 2017
Despite an aging population and underrepresentation of elderly patients in clinical trials, studies on elderly patients with metastatic pancreatic cancer are scarce.
Besselink, M.G. (Marc), Haj Mohammad, N. (Nadia), Laarhoven, H.W.M. (Hanneke) van, Lemmens, V.E.P.P. (Valery), Portielje, J.E.A. (Johanneke ), van der Geest, L.G.M. (Lydia G.M.), Wilmink, J.W. (Johanna)   +6 more
core   +3 more sources

Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF‐PARAGON study)

International Journal of Cancer, EarlyView.
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Thorsten O. Goetze, Salah‐Eddin Al‐Batran, Ruediger Liersch, Lars Scheuer, Thomas Goehler, Ulrich Kaiser, Claudio Denzlinger, Stephan Brandl, Daniel Pink, Jens Uhlig, Michael Maasberg, Maria Loose, Marina Schaaf, Disorn Sookthai, Bianca Zäpf, Claudia Pauligk, Timursah Habibzade, Ralf‐Dieter Hofheinz, Christine Koch, for the AIO Study Group   +19 more
wiley   +1 more source

Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab‐paclitaxel

International Journal of Cancer, EarlyView.
What's New? Adaptive immune responses are typically limited in pancreatic ductal adenocarcinoma, resulting in minimal efficacy of immune checkpoint inhibitors. Tumor Treating Fields (TTFields) therapy, which uses low‐intensity intermediate‐frequency electric fields to disrupt cancer cell processes, has been approved for certain cancers.
Tal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, Tali Voloshin, Lilach Koren, Bella Koltun, Cfir David, Kerem Wainer‐Katsir, Avital Vorontsova, Boris Brant, Simona Zisman‐Rozen, Hila M. Ene, Roni Frechtel‐Gerzi, Shay Cahal, Anat Klein‐Goldberg, Lena Lifshitz, Efrat Zemer Tov, Mai Shai, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti   +21 more
wiley   +1 more source

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report

Case Reports in Oncology, 2017
Thymic carcinomas are rare malignant tumors, located in the anterior mediastinum. For the treatment of these carcinomas, several chemotherapy regimens have been suggested, including carboplatin plus paclitaxel.
Kunihiko Funaishi, Masahiro Yamasaki, Naomi Saito, Wakako Daido, Sayaka Ishiyama, Naoko Deguchi, Masaya Taniwaki, Nobuyuki Ohashi   +7 more
doaj   +1 more source

nab-Paclitaxel for the treatment of pancreatic cancer.

Cancer management and research, 2017
Nanoparticle albumin-bound paclitaxel (nab-P) plus gemcitabine (Gem) became a standard treatment option for metastatic pancreatic cancer (MPC) following positive results from a global phase III trial (MPACT). A large number of studies have now published results on the use of nab-P/Gem to treat advanced and early-stage disease, warranting a ...
openaire   +4 more sources

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study

ClinicoEconomics and Outcomes Research, 2013
Carlo Lazzaro,1 Roberto Bordonaro,2 Francesco Cognetti,3 Alessandra Fabi,3 Sabino De Placido,4 Grazia Arpino,4 Paolo Marchetti,5 Andrea Botticelli,5 Paolo Pronzato,6 Elisa Martelli7 1Studio di Economia Sanitaria, Milan, Italy; 2Public Hospital Trust ...
Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E   +9 more
doaj  

Microbial metabolites in tumor epigenetic regulation

iMeta, EarlyView.
The gut microbiome modulates tumor epigenetic regulation through bioactive metabolites derived from dietary substrates. Microbiota‐produced SCFAs, secondary BAs, one‐carbon metabolites, and tryptophan‐derived ligands regulate histone acetylation, DNA methylation, and chromatin remodeling via HDAC, DNMT, AhR, and metabolic cofactor‐dependent pathways ...
Wangzheqi Zhang, Haoling Zhang, Yan Liao, Shuya Jiang, Haolong Zhang, Chenwei Huang, Zhijing Song, Rui Zhao, Ping Lu, Xiaohong Kang, Eryan Kong, Yalin Zhu, Wei Wang, Xuesong Liu, Yisheng Chen, Zhiwen Luo, Zhaoyu Li, Di Wang, Na Xing, Yadong Guo, Jingjing Zhang, Xiaojing Wang, Wenyi Wang, Mowaffaq Adam, Bakiah Shaharuddin, Muhamad Yusri Musa, Doblin Sandai, Chenglong Zhu, Aimin Jiang, Peng Luo, Zhijie Zhao, Zui Zou   +31 more
wiley   +1 more source